PDCD1 and neoplasm: For non-responders, the PD-1 signaling is not a rate-limiting rheostat of the tumor immune cycle, and it is not enough to restore antitumor immunity by blocking PD-1 or PD-L1, which is expensive and can be accompanied by immune-related adverse events (70) (irAEs) (Table 2).